REVELATION BIOSCIENCES, INC. (REVB): Entry into a Material Definitive Agreement
REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 3 revb-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 RIGHTS AGREEMENT dated as of July 10, 2026 by and between REVELATION BIOSCIENCES, INC. and CONTINENTAL STOCK TRANSFER & TRUST CO. Table of Contents SECTION 1. Certain Definitions 3 SECTION 2. Appointment of Rights Agent 10 SECTION
How this was made
The 30-second read
Why it matters
A rights plan typically activates when an entity becomes an “Acquiring Person” (beneficial ownership threshold stated as 10% or 15% for certain passive investors), potentially diluting economics for would-be acquirers and changing takeover dynamics.
Market read
This is a governance and takeover-risk disclosure via an 8-K, with potential implications for M&A expectations but no explicit transaction or bid is described in the excerpt.
What to watch
The market may focus on the exact distribution date, redemption/exchange triggers, and any board rationale, none of which are fully detailed in the provided excerpt.
Background
The company’s board authorized and declared a dividend of one preferred share purchase right for each common share outstanding on July 10, 2026, under a Rights Agreement dated July 10, 2026.
Ticker impact
Revelation Biosciences filed an 8-K for a new Rights Agreement, declaring a preferred share purchase right tied to its common shares.
Near-term impact likely limited unless investors interpret the plan as signaling takeover risk or governance concerns.
The text confirms entry into a material definitive agreement and describes the rights plan mechanics (10% threshold for an acquiring person), but provides no deal, financing, or explicit hostile bid context.
Market effects
Rights plans are common across biotech and other sectors; read-through is mainly governance and M&A optionality rather than operating fundamentals.
Primarily US-listed equity sentiment; limited cross-market effect expected.
Low, unless the plan is interpreted as a response to a specific global acquirer or bid (not stated here).
Counterpoint
Investors may view the rights plan as routine and not a signal of imminent M&A, so price reaction could be muted.
Key entities
- issuerREVELATION BIOSCIENCES, INC.
Subject of the 8-K and party to the Rights Agreement.
- rights_agentCONTINENTAL STOCK TRANSFER & TRUST CO.
Rights agent appointed under the Rights Agreement.
